AI culture inversion meets accelerating cure trials

Global active cure-related trials reached 21,347, while 19 new Wire signals and 16 new Cure research items appeared in the last 24 hours—an unusually dense day across both the capital/AI and lab lanes. On the Wire side, signals cluster around an “inversion” of how models convert input into new, user-shaped experiences (Engram) and around who gains leverage as AI narratives compete with credibility and access (Meta timing; Amodei dining with Trump). On the Cure side, advances range from whole lamella cryo-FIB/cryogenic electron tomography to patient-derived organoid–T cell co-culture platforms and CAR-T engineering that targets mucin-rich glycocalyx features—exactly the kind of translational instrumentation and functional testing that tends to compound. Together, the pattern suggests the transition is not only about smarter models, but about faster, better evidence loops that can carry cure work downstream. The window is still open.